Flora Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 57 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 7.09 M
- Revenue Growth 0.61%
- Profit Growth -41.65%
- Ebitda 331.92%
- Net Worth -3.49%
- Total Assets -6.28%
About Flora Pharma
Flora Pharma Private Limited (FPPL) was founded in India on 08 November 1967 and has a glorious history of 57 years and three months.Its registered office is in Kanpur Nagar, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹7.09 M.
Khemanand Bhatt, Chandra Yadav, and Deepak Gupta serve as directors at the Company.
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232UP1967PTC003180
- Company No.
003180
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Nov 1967
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Flora Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Khemanand Bhatt  | Additional Director | 23-Oct-2021 | Current |
| Chandra Yadav | Additional Director | 23-Oct-2021 | Current |
| Deepak Gupta | Director | 01-Apr-1984 | Current |
Financial Performance of Flora Pharma.
Flora Pharma Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 0.61% increase. The company also saw a substantial fall in profitability, with a 41.65% decrease in profit. The company's net worth dipped by a decrease of 3.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Flora Pharma?
In 2021, Flora Pharma had a promoter holding of 60.00% and a public holding of 40.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹7.09 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.71 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Jun 2010 | State Bank Of India | ₹0.40 M | Open |
| 25 May 1993 | State Bank Of India | ₹6.00 M | Open |
| 07 Nov 1990 | State Bank Of India | ₹0.30 M | Open |
| 21 Dec 1988 | State Bank Of India | ₹0.09 M | Open |
| 29 Aug 1985 | State Bank Of India | ₹0.30 M | Open |
How Many Employees Work at Flora Pharma?
Flora Pharma has a workforce of 3 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Flora Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Flora Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
